Anne Kiltie BM, BCh, MA, DM, MRCP(UK), FRCR
- Cancer and Haematology
- Dr Martin Kerr, PhD
- Dr Eva McGrowder, PhD
- Ms Naomi Sharma, PhD, Intermediate Clinical Fellow
- Dr Blaz Groselj, DPhil Student
- Ms Sarah Jevons, DPhil Student
- Ms Alexa Walker, DPhil Student
- Ms Katalin Karaszi, Research Technician
- Ms Helen Scott, Research Technician
- Groselj B, Sharma N L, Hamdy F C, Kerr M, and Kiltie A E (2013) Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer, 108(4):748-54.
- Qiao Boling, Kerr Martin, Groselj Blaz, Teo Mark TW, Knowles Margaret A, Bristow Robert G, Phillips Roger M, and Kiltie Anne E (2013) Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res, 73(5):1611-20.
- Teo Mark TW, Landi Debora, Taylor Claire F, Elliott Faye, Vaslin Laurence, Cox David G, Hall Janet, Landi Stefano, Bishop D T, and Kiltie Anne E (2012) The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis, 33(3):581-6.
- Choudhury A, Swindell R, Logue J P, Elliott P A, Livsey J E, Wise M, Symonds P, Wylie J P, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke N W, Kiltie A E, and Cowan R A (2011) Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol, 29(733-8).
- Qiao Boling, Ansari Abdul-Haq, Scott Gina B, Sak Sei C, Chambers Philip A, Elliott Faye, Teo Mark TW, Bentley Johanne, Churchman Michael, Hall Janet, Taylor Claire F, Bishop Timothy D, Knowles Margaret A, and Kiltie Anne E (2011) In vitro functional effects of XPC gene rare variants from bladder cancer patients. Carcinogenesis, 32(4):516-21.
|Tel||+44 (0) 1865 617352|
|Contact address||United Kingdom|
The three primary aims of our work are
- To investigate the mechanisms underlying the non-homologous end-joining defective/microhomology-mediated end-joining phenotype seen in muscleinvasive bladder cancer, and to exploit this clinically in combined radiotherapy/biological treatments.
- To investigate expression of the DNA damage signalling protein MRE11 as a potential biomarker for prediction of outcome following radiotherapy and chemotherapy, and to establish the role of other such biomarkers. This should ultimately allow patient selection for optimal bladder cancer treatment, thus increasing overall cure rates.
- To establish which DNA repair gene germ-line variants implicated in bladder cancer risk would allow identification of high-risk idividuals, who would benefit from prophylactic intervention with targeted screening and lifestyle intervention to minimize bladder cancer mortality.
October 2009 to present Clinical Group Leader, Gray Institute for Radiation Oncology and Biology, University of Oxford and Honorary Consultant Clinical Oncologist, Oxford Radcliffe NHS Trust.
Nov 2001 - Sept 2009 Senior Lecturer/Honorary Consultant Clinical Oncologist (Radiotherapist), St James's University Hospital and St James's Institute of Oncology, Leeds.
Oct 1999 - Oct 2001 Clinical Research Fellow, ICRF Clare Hall Laboratories, South Mimms, Herts.
Awards, Training and Qualifications
2006 Cancer Research UK Clinician Scientist Fellowship.
1998 ESTRO Varian Radiobiology Research Award.
1999 DM, University of Oxford
1995 FRCR (Clinical Oncology)
1992 MRCP (UK)
1989 MA, Sidney Sussex College, Cambridge University
1988 BM BCh, Oxford University Medical School
1985 BA, Sidney Sussex College, Cambridge University